WALTHAM, Mass • 2023-02-07

BostonGene Showcases Comprehensive Approach to Precision Medicine at Immuno-Oncology 360°

5 min to read

BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York
WALTHAM, Mass, February 7, 2023

BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York. The event spans the ecosystem responsible for the development of Immuno-Oncology therapies and attracts leading pharma and biotech, academic key opinion leaders, life science investors, patient advocacy, technologists and services companies.

BostonGene session details can be found below:



Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Thursday, February 9 | 4:50 PM ET

  • Speaker: Michael Goldberg, PhD, Director of Immunology, BostonGene


This session will address BostonGene’s comprehensive profile of a patient’s disease for therapy selection and stratification for IO clinical trials to improve outcomes by using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with deep immunoprofiling and best-in-class analytics.

"With BostonGene's transcriptional profiling and sophisticated analytics, we can perform detailed surveys of functional immune programs in the tumor microenvironment. Our comprehensive genomic profiling platform and cutting-edge bioinformatics can stratify patients into IO response groups and pair individuals with the most effective therapy,” said Michael Goldberg, PhD, Director of Immunology at BostonGene. "I look forward to participating at IO360° and to presenting how our expanded framework that evaluates immune escape mechanisms within the TME could facilitate the rational design of IO combinations to improve patient outcomes."

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com